DEF: TransMedics Group Reports Strong 2024 Performance and Announces Annual Shareholder Meeting

TransMedics Group announces its 2025 Annual Meeting of Shareholders and highlights a successful 2024 marked by significant revenue growth and profitability.

Summary

• TransMedics Group had a remarkable year in 2024, completing over 3,700 U.S. OCS cases and generating $441.5 million in total revenue, representing 83% year-over-year growth.
• The company achieved operating profitability for the first time in 2024, with $37.5 million in operating profit and $35.5 million in net income.
• TransMedics generated $48.8 million in positive cash flow from operating activities for the full year.
• The company is launching two strategic next-gen clinical programs in heart and lung transplantation and investing in its next generation OCS technology platform.
• The Annual Meeting of Shareholders will be held on May 22, 2025, to elect directors, approve executive compensation, and ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm.
• The Board recommends voting for the election of all eight director nominees, the approval of executive compensation, and the ratification of the accounting firm appointment.

Sentiment

Score: 9

Explanation: The document expresses a highly positive sentiment due to the company's strong financial performance, strategic growth initiatives, and optimistic future outlook. The achievement of profitability and positive cash flow significantly boosts the sentiment.

Positives

• Significant revenue growth of 83% year-over-year, reaching $441.5 million.
• Achievement of operating profitability with $37.5 million in operating profit and $35.5 million in net income.
• Positive cash flow from operating activities of $48.8 million.
• Successful completion of over 3,700 U.S. OCS cases.
• Expansion of market share in liver and heart markets.
• Strategic investments in next-gen clinical programs and OCS technology platform.

Future Outlook

TransMedics expects 2025 to be a transformative year and anticipates continued growth into the foreseeable future, driven by strategic investments and next-generation clinical programs.

Management Comments

• Waleed Hassanein, M.D., Founder, President and Chief Executive Officer, expressed pride in the company's success and gratitude to the team, clinical users, shareholders, and Board of Directors.
• Management believes they are laying a solid foundation for continued growth into the foreseeable future.

Industry Context

TransMedics is transforming the field of organ transplantation globally with its OCS technology and NOP clinical services, playing an integral role in driving growth in overall national liver, heart, and lung transplant volumes in the U.S.

Comparison to Industry Standards

• The document does not contain specific comparisons to industry standards or benchmarks.
• The document does not contain specific comparisons to comparable companies or projects.

Management Changes

Related Party Transactions

• Dr. Amira Hassanein, the sister of Waleed H. Hassanein, M.D., our President and Chief Executive Officer, is employed by us as Product Director for OCS Lung Program and reports to our Chief Commercial Officer. Her compensation, including salary and bonus, earned in the fiscal year ended December 31, 2024 was $659,954, consistent with other employees at her level and responsibility.

Stakeholder Impact

• Shareholders: Positive financial results and strategic growth initiatives are expected to increase shareholder value.
• Employees: Continued growth and profitability may lead to increased job security and potential for career advancement.
• Customers: Investments in technology and clinical programs aim to improve patient outcomes and expand access to organ transplantation.
• Suppliers: Increased demand for OCS technology and services may lead to increased business opportunities for suppliers.

Next Steps

• Elect eight (8) directors, each to serve until the 2026 Annual Meeting of Shareholders.
• Approve, on a non-binding advisory basis, the compensation of our named executive officers.
• Ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025.

Key Dates

Keywords

TransMedics, organ transplantation, OCS, revenue, profitability, shareholders, executive compensation, directors, PricewaterhouseCoopers, Annual Meeting